Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash & Current Investments (2016 - 2026)

Summit Therapeutics filings provide 13 years of Cash & Current Investments readings, the most recent being $106.8 million for Q1 2026.

  • Quarterly Cash & Current Investments fell 49.57% to $106.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $106.8 million through Mar 2026, down 49.57% year-over-year, with the annual reading at $225.6 million for FY2025, 45.29% down from the prior year.
  • Cash & Current Investments hit $106.8 million in Q1 2026 for Summit Therapeutics, down from $225.6 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $648.6 million in Q4 2022 and bottomed at $23.8 million in Q3 2023.
  • Average Cash & Current Investments over 5 years is $200.0 million, with a median of $211.8 million recorded in 2025.
  • The largest annual shift saw Cash & Current Investments tumbled 88.99% in 2023 before it surged 935.93% in 2025.
  • Summit Therapeutics' Cash & Current Investments stood at $648.6 million in 2022, then tumbled by 88.99% to $71.4 million in 2023, then surged by 477.32% to $412.3 million in 2024, then plummeted by 45.29% to $225.6 million in 2025, then tumbled by 52.64% to $106.8 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Cash & Current Investments are $106.8 million (Q1 2026), $225.6 million (Q4 2025), and $238.9 million (Q3 2025).